Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 27, 2014 10:15 ET | Source: Endocyte, Inc.

Phase 2b TARGET Trial Results Show Improved Survival in Adenocarcinoma Non-Small Cell Lung Cancer Patients Treated With Endocyte's Vintafolide

- Data Presented Today as Late-Breaker at European Society for Medical Oncology (ESMO) 2014 Congress in Madrid - - Interim Update of Overall Survival Analysis Shows 30 Percent Reduction of Risk of...
September 27, 2014 09:01 ET | Source: Canon Solutions America

Canon Solutions America's Paper Partners Featured at Graph Expo

MELVILLE, N.Y., Sept. 27, 2014 (GLOBE NEWSWIRE) -- Canon Solutions America, Inc., a subsidiary of Canon U.S.A., Inc., will showcase its unique inkjet printing capabilities at the Canon U.S.A. booth,...
September 27, 2014 08:00 ET | Source: Brower Piven, A Professional Corporation

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Rocket Fuel Inc. to Contact Brower Piven Before the November 3, 2014 Lead Plaintiff Deadline in Class Action Lawsuit -- FUEL

STEVENSON, Md., Sept. 27, 2014 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the...
September 27, 2014 06:45 ET | Source: Novartis Pharma AG

Patients lived average of 18 months without cancer progressing when taking Novartis' Zykadia(TM) as their first ALK inhibitor for ALK+ NSCLC

Longest median progression-free survival (PFS) ever reported in this ALK+ non-small cell lung cancer patient population, most who received prior chemotherapy[1] Zykadia (ceritinib) achieved...
September 27, 2014 05:37 ET | Source: Brim hf.

HB Grandi hf. Flöggun LSR - Dagsetning viðskipta 26. september 2014

Sjá viðhengi...
September 27, 2014 05:00 ET | Source: Novartis Pharma AG

Novartis drug Afinitor is first treatment for advanced pancreatic NET to provide overall survival of more than 3.5 years in Phase III trial

Afinitor led to an unprecedented median overall survival of 44 months, which represents a clinically meaningful while not statistically significant improvement[1] Pancreatic NET (pNET) affects...
September 27, 2014 03:05 ET | Source: Eccentry Holidays Sunny Isles

Eccentry Holidays Sunny Isles Provides Families with Great Time Saving Disney World Tips for the Fall

MIAMI, Fla., Sept. 27, 2014 (GLOBE NEWSWIRE) -- via PRWEB - Millions of families choose to visit Walt Disney World in Orlando, Florida, every year for their annual family vacation. Eccentry Holidays...
September 27, 2014 03:03 ET | Source: Scholar Base

Child Enrichment Centre, Scholar Base, Today Announces its Annual Open Day Featuring Performances from Students and an Exclusive Promotional Offer for New Registrations

KUALA LUMPUR, Malaysia, Sept. 27, 2014 (GLOBE NEWSWIRE) -- via PRWEB - Child development centre, Scholar Base, today announces its annual Open Day, raising public awareness for the centre's programmes...
September 26, 2014 23:22 ET | Source: The Rosen Law Firm PA

EQUITY ALERT: The Rosen Law Firm Reminds IRadimed Corporation Investors of Important Deadline in Class Action Filed by Firm -- IRMD

NEW YORK, Sept. 26, 2014 (GLOBE NEWSWIRE) -- The Rosen Law Firm reminds purchasers of IRadimed Corporation (Nasdaq:IRMD) common stock between July 15, 2014 and September 2, 2014, of the important...
September 26, 2014 23:11 ET | Source: The Rosen Law Firm PA

EQUITY ALERT: Rosen Law Firm Reminds Marrone Bio Innovations, Inc. Investors of Important Class Action Deadline - MBII

NEW YORK, Sept. 26, 2014 (GLOBE NEWSWIRE) -- The Rosen Law Firm, P.A. reminds purchasers of Marrone Bio Innovations, Inc. securities (Nasdaq:MBII) between March 7, 2014 and September 2, 2014, of the...

1 ...222875 222876 222877 ...320519